Patents and Licenses

OptiGen holds the exclusive license for these tests from Cornell Research Foundation, Inc.:
CEA/CH Patent Pending, International
CSNB US Patent No. 6,201,114 and US Patent No. 6,428,958
prcd-PRA US Patent No. 5,804,388
prcd-PRA Canadian Patent No. CA2306194
prcd-PRA U.K. Patent No. 2 341 926
prcd-PRA Mutation US Patent No. 7,312,037
prcd-PRA Mutation Patent, International EPO No. PCT/US2006/047661
prcd-PRA LD Patent Pending, International

OptiGen holds the exclusive license for U.S. and Canada and a non-exclusive license for other regions from the inventors at U. of New South Wales and the Border Collie Club of NSW, Australia, for this test:
NCL Patent Pending, International

OptiGen holds the exclusive license for this test from the inventors at the Swedish University in Uppsala, Sweden:
CLAD Patent No. 6,210,897

OptiGen holds the exclusive license for this test from Stanford University School of Medicine:
NARC Patent Pending

OptiGen holds the exclusive U.S. and Canada license for this test from Merlogen, LLC:
FN Patent No. 7,285,388

OptiGen tests are provided pursuant to a license from Genetic Technologies Limited for their Non-Coding/Mapping Patents.